Vancouver, BC – Dr Pierre Meulien, the chief scientific officer of Genome BC, has been appointed the new president & CEO of Genome Canada.
“I fully enjoyed my 3.5 years in the CSO role with Genome BC and the CEO opportunity with Genome Canada will provide me with an increased scope to continue delivering on the promise of genomics for all Canadians,” says Dr Meulien. “I look forward to working with end-users to improve the utility and application of genomics technologies in order to enhance industry uptake across all economic sectors important to Canada.”
While at Genome BC, Dr Meulien was responsible for developing an international strategy that resulted in partnerships with the European Union, Chile, Australia, and Norway. He also spearheaded an international consortium to sequence the Atlantic salmon genome, which will lead to better management of wild fish stocks and breeding selection for commercially important traits.
Prior to Genome BC, Dr Meulien was the founding CEO of the Dublin Molecular Medicine Centre (now Molecular Medicine Ireland), and held leadership roles with a number of other companies around the world including Aventis Pasteur in Toronto (senior vice president of R&D), and in Lyon, France (director of research). His academic credentials include a PhD from the University of Edinburgh and a post-doctoral appointment at the Institut Pasteur in Paris.
Genome Canada is the primary funder and information resource relating to genomics in Canada.